Night Driving After Trifocal Versus Monofocal IOL Implantation
Key facts
- Who runs it
- Jin Yang
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 30 Aug 2026
- Expected to end
- 31 Aug 2031
- Type of study
- Observational, 2 groups
- Treatments tested
- AcrySof IQ PanOptix TFNT00 Trifocal Intraocular Lens
- Alcon Monofocal Intraocular Lens
- Record updated
- 10 August 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Adults aged 18 to 85 years
- Scheduled to undergo bilateral phacoemulsification with in-the-bag intraocular lens implantation
- Both eyes scheduled to receive the same type and model of either an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens
- Possession of a valid motor vehicle driving license
- Stable night-driving behavior during the previous 3 months, with night driving occurring at least twice per month
- Lens Opacities Classification System III nuclear opalescence grade of 4 or lower in both eyes
- Expected intraocular lens power between +10.0 D and +36.0 D, inclusive, in both eyes
- Ability to understand the purpose and procedures of the study and independently complete the VND-Q and visual quality questionnaires
- Willingness to provide written informed consent and complete the scheduled postoperative follow-up visits
Who cannot take part
- History of ocular trauma affecting visual function, previous intraocular surgery, or previous corneal refractive surgery in either eye
- Use of medication judged by the investigator to increase surgical risk or affect visual function, including amiodarone, chlorpromazine, ethambutol, digitalis, or chloroquine
- Requirement for a combined ocular procedure, including limbal relaxing incisions, intraocular drug injection, retinal laser treatment, or another combined procedure judged inappropriate by the investigator
- Any ocular disease that may affect postoperative visual acuity, contrast sensitivity, mesopic visual function, or questionnaire assessment, including but not limited to irregular corneal astigmatism, corneal scar, corneal degeneration, keratoconus, keratitis, corneal dystrophy, uveitis, severe iris atrophy, intraoperative floppy iris syndrome, microphthalmos, macrophthalmos, color vision deficiency, active ocular inflammation, advanced glaucoma or uncontrolled intraocular pressure, macular disease, retinal pigment epithelial disease, diabetic retinopathy, retinal detachment, choroidal detachment, or optic atrophy
- A high risk of zonular rupture or an contraindication to in-the-bag intraocular lens implantation, including zonular weakness, zonular dialysis, lens subluxation or dislocation, pseudoexfoliation syndrome, Marfan syndrome, posterior capsule rupture, or cyclodialysis; Severe or unstable systemic disease, including systemic lupus erythematosus or Sjögren syndrome
- Severe anxiety, depression, or another significant psychiatric disorder
- Any other condition judged by the investigator to make participation inappropriate
- Corneal endothelial cell density below 1,500 cells/mm² in either eye
- Strabismus, amblyopia, or nystagmus in either eye
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Cataract or presbyopia correction
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective observational cohort study will compare night-driving visual difficulty and visual disturbances after bilateral implantation of an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens in adults undergoing cataract surgery. The type of intraocular lens will be selected by each participant and the treating ophthalmologist as part of routine clinical care, and will not be assigned by the investigators.
Read full original descriptionShow less
Eligible participants must have a valid motor vehicle driving license and a stable history of night driving during the previous 3 months. The primary outcome will be the total score of the Visual Function and Night Driving Questionnaire (VND-Q) at 3 months postoperatively. Secondary assessments will include glare adaptation, self-rated night-driving quality and driving speed, changes in night-driving behavior, visual disturbances, distance, intermediate and near visual acuity, contrast sensitivity, whole-eye aberrations, pupil diameter, defocus performance, reading speed, spectacle independence, and participant satisfaction.
The 2 groups in the trial
- Trifocal IOL Group
Undergo bilateral phacoemulsification and implantation of Alcon trifocal intraocular lens in both eyes
Treatment: AcrySof IQ PanOptix TFNT00 Trifocal Intraocular Lens
- Monofocal IOL Group
Undergo bilateral phacoemulsification and implantation of Alcon monofocal intraocular lens in both eyes
Treatment: Alcon Monofocal Intraocular Lens
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Night-Driving Visual Quality and Visual Disturbances After Bilateral Trifocal Versus Monofocal Intraocular Lens Implantation: A Prospective Observational Cohort Study
- Criteria questions
- Built from NCT07755189, who can take part
- Record updated
- 10 August 2026